Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases

Abstract EN

Farnesoid X receptor (FXR) is a bile acid receptor encoded by the Nr1h4 gene.

FXR plays an important role in maintaining the stability of the internal environment and the integrity of many organs, including the liver and intestines.

The expression of FXR in nondigestible tissues other than in the liver and small intestine is known as the expression of “nonclassical” bile acid target organs, such as blood vessels and lungs.

In recent years, several studies have shown that FXR is widely involved in the pathogenesis of various respiratory diseases, such as chronic obstructive pulmonary disease, bronchial asthma, and idiopathic pulmonary fibrosis.

Moreover, a number of works have confirmed that FXR can regulate the bile acid metabolism in the body and exert its anti-inflammatory and antifibrotic effects in the airways and lungs.

In addition, FXR may be used as a potential therapeutic target for some respiratory diseases.

For example, FXR can regulate the tumor microenvironment by regulating the balance of inflammatory and immune responses in the body to promote the occurrence and development of non-small-cell lung cancer (NSCLC), thereby being considered a potential target for immunotherapy of NSCLC.

In this article, we provide an overview of the internal relationship between FXR and respiratory diseases to track the progress that has been achieved thus far in this direction and suggest potential therapeutic prospects of FXR in respiratory diseases.